The effect of hemoperfusion on treatment outcomes in COVID-19 patients with respiratory failure: a prospective study DOI Open Access
Effat Rafiee, Samad Ghodrati,

Ayoub Pezeshgi

et al.

Immunopathologia Persa, Journal Year: 2023, Volume and Issue: unknown

Published: July 29, 2023

Introduction: COVID-19 emerged as a global clinical threat following an outbreak in China late 2019. Objectives: The aim of the current study was to assess effect hemoperfusion patients with respiratory failure. Patients and Methods: In this prospective study, total 98 over age 18 positive polymerase chain reaction (PCR) test were investigated. divided into two groups; control group consisting 47 who did not receive hemoperfusion, exposed 51 met criteria for hemoperfusion. Various parameters including complete blood cell counts, serum bilirubin, creatinine, C-reactive protein (CRP), interleukin 6 (IL-6) levels evaluated all patients. Results: results our revealed statistically significant difference intensive care unit (ICU) admission between groups. Hospitalization time (19.941±1.75 versus 14.615±1.39, P=0.021) ICU (14.98±1.30 9.62±1.15; P=0.003) significantly higher received Regarding mortality rate, only 36.7% survived; however, there no observed groups (P=0.34). Conclusion: conclusion, findings indicate that failure led increase hospital stay compared those without Further research is needed determine optimal timing frequency improve treatment outcomes

Language: Английский

Efferent methods of therapy for critical illness DOI Open Access
Аndrey М. Sarana, Sergey G. Shcherbak, Dmitry A. Vologzhanin

et al.

Physical and rehabilitation medicine medical rehabilitation, Journal Year: 2024, Volume and Issue: 6(1), P. 49 - 72

Published: March 22, 2024

Extracorporeal blood purification is intended to eliminate dysregulation of the immune system. The concept extracorporeal therapy based on nonspecific clearance inflammatory mediators and triggers, which attenuates systemic expression mediators. main types are hemoadsorption plasma exchange. Hemoadsorption used primarily as an adjuvant treatment for septic shock other severe conditions, including forms COVID-19 with cytokine storm. Reliable data demonstrating benefit in critically ill patientsis limited. Recommendations use devices often incomplete or questionable interpretations available data. Given lack evidence inflammation, sepsis, liver failure rhabdomyolysis, its routine clinical practice not justified until mechanisms underlying these findings fully elucidated. Plasma replacement a potentially life-saving invasive procedure that replaces substitute fluid (saline, albumin solution, fresh frozen plasma, combination these) risk side effects complications. There still uncertainty regarding timing, type exchange, volume frequency filtration. Although considered be relatively safe, there insufficient support inclusion sepsis protocols. Reports methods patients refractory inflammation provide decreased levels biomarkers, improved hemodynamic parameters, organ failure. However, according results randomized trials, does affect outcomes, some even increases mortality. To clarify effectiveness therapy, it necessary study interaction target non-target components large-scale controlled trials assessing ability this improve outcomes.

Language: Английский

Citations

1

Impact of extracorporeal hemadsorption on mortality in critically ill COVID-19 patients in the intensive care unit DOI
Özlem Çakın, Melike Yüce Aktepe, Orbay Harmandar

et al.

The International Journal of Artificial Organs, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 13, 2024

Background: The consequences of COVID-19, such as respiratory failure and mortality, require the search for fast effective solutions. aim this retrospective study is to determine effect extracorporeal hemadsorption on mortality in severe COVID-19 cases hospitalized intensive care unit (ICU). Methods: Our retrospective, single-center, observational. included ICU patients diagnosed with who received treatment between March 2020 December 2020. Effects were examined by comparing pre- post-hemadsorption values. Results: Seventeen study. rate was 64.7%. After hemadsorption, an increase observed lymphocyte numbers, APACHE-II, SOFA values ( p = 0.026, 0.043, 0.033; respectively). A significant decrease CRP fibrinogen levels 0.003 0.005; In non-surviving patient group, SOFA, procalcitonin found be high before after procedure 0.002, 0.048, 0.06; Conclusion: patients, APACHE-II scores may useful predicting effectiveness hemadsorption. that higher at baseline had a These findings show use scoring systems determining which should receive performed early stages disease.

Language: Английский

Citations

0

Beyond conventional care: The therapeutic potential of hemoperfusion in severe COVID-19 DOI

John Vásquez-Torres,

Ramsés Dávila-Collado,

Leyla Abdalah-Perez

et al.

World Journal of Critical Care Medicine, Journal Year: 2024, Volume and Issue: 13(4)

Published: Oct. 31, 2024

Hemoperfusion (HP) is an extracorporeal blood purification modality utilized to remove small- medium-sized molecules, such as toxins and cytokines, that are difficult by conventional hemodialysis. In clinical practice, HP has been successfully used a salvage therapy for drug overdose occasionally in patients with liver failure sepsis.

Language: Английский

Citations

0

The effect of hemoperfusion on treatment outcomes in COVID-19 patients with respiratory failure: a prospective study DOI Open Access
Effat Rafiee, Samad Ghodrati,

Ayoub Pezeshgi

et al.

Immunopathologia Persa, Journal Year: 2023, Volume and Issue: unknown

Published: July 29, 2023

Introduction: COVID-19 emerged as a global clinical threat following an outbreak in China late 2019. Objectives: The aim of the current study was to assess effect hemoperfusion patients with respiratory failure. Patients and Methods: In this prospective study, total 98 over age 18 positive polymerase chain reaction (PCR) test were investigated. divided into two groups; control group consisting 47 who did not receive hemoperfusion, exposed 51 met criteria for hemoperfusion. Various parameters including complete blood cell counts, serum bilirubin, creatinine, C-reactive protein (CRP), interleukin 6 (IL-6) levels evaluated all patients. Results: results our revealed statistically significant difference intensive care unit (ICU) admission between groups. Hospitalization time (19.941±1.75 versus 14.615±1.39, P=0.021) ICU (14.98±1.30 9.62±1.15; P=0.003) significantly higher received Regarding mortality rate, only 36.7% survived; however, there no observed groups (P=0.34). Conclusion: conclusion, findings indicate that failure led increase hospital stay compared those without Further research is needed determine optimal timing frequency improve treatment outcomes

Language: Английский

Citations

0